How to buy Aurinia Pharmaceuticals stock

Aurinia Pharmaceuticals Inc is a biotechnology business based in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Aurinia Pharmaceuticals employs 294 staff and has a trailing 12-month revenue of around 0.00.

Aurinia Pharmaceuticals share price

Use our graph to track the performance of AUPH stocks over time.

Aurinia Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-05-07.

52-week range	$11.61 - $18.72
50-day moving average	$13.82
200-day moving average	$14.53
Wall St. target price	$11.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.70

Buy Aurinia Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aurinia Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aurinia Pharmaceuticals Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aurinia Pharmaceuticals financials

Revenue TTM	$50.1 million
Gross profit TTM	$-209,000
Return on assets TTM	-16.54%
Return on equity TTM	-29.07%
Profit margin	-204.88%
Book value	$3.22
Market capitalisation	$1.3 billion

TTM: trailing 12 months

Shorting Aurinia Pharmaceuticals shares

There are currently 8.5 million Aurinia Pharmaceuticals shares held short by investors – that's known as Aurinia Pharmaceuticals's "short interest". This figure is 4.8% up from 8.1 million last month.

There are a few different ways that this level of interest in shorting Aurinia Pharmaceuticals shares can be evaluated.

Aurinia Pharmaceuticals's "short interest ratio" (SIR)

Aurinia Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aurinia Pharmaceuticals shares currently shorted divided by the average quantity of Aurinia Pharmaceuticals shares traded daily (recently around 2.5 million). Aurinia Pharmaceuticals's SIR currently stands at 3.39. In other words for every 100,000 Aurinia Pharmaceuticals shares traded daily on the market, roughly 3390 shares are currently held short.

However Aurinia Pharmaceuticals's short interest can also be evaluated against the total number of Aurinia Pharmaceuticals shares, or, against the total number of tradable Aurinia Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aurinia Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Aurinia Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Aurinia Pharmaceuticals shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aurinia Pharmaceuticals.

Find out more about how you can short Aurinia Pharmaceuticals stock.

Aurinia Pharmaceuticals share dividends

We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.

Have Aurinia Pharmaceuticals's shares ever split?

Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 22 October 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.

Aurinia Pharmaceuticals share price volatility

Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as $11.61 up to $18.7199. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 0.3406. This would suggest that Aurinia Pharmaceuticals's shares are less volatile than average (for this exchange).

Aurinia Pharmaceuticals overview

Aurinia Pharmaceuticals Inc. , a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. , Ltd. The company is headquartered in Victoria, Canada. .

Frequently asked questions

• What percentage of Aurinia Pharmaceuticals is owned by insiders or institutions?

  Currently 7.204% of Aurinia Pharmaceuticals shares are held by insiders and 50.903% by institutions.

• How many people work for Aurinia Pharmaceuticals?

  Latest data suggests 294 work at Aurinia Pharmaceuticals.

• When does the fiscal year end for Aurinia Pharmaceuticals?

  Aurinia Pharmaceuticals's fiscal year ends in December.

• Where is Aurinia Pharmaceuticals based?

  Aurinia Pharmaceuticals's address is: 4464 Markham Street, Victoria, BC, Canada, V8Z 7X8

• What is Aurinia Pharmaceuticals's ISIN number?

  Aurinia Pharmaceuticals's international securities identification number is: CA05156V1022

• What is Aurinia Pharmaceuticals's CUSIP number?

  Aurinia Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 05156V102